CPC-070 Importance of Residual Investigational Medicinal Product Count
نویسندگان
چکیده
منابع مشابه
Commentary: considerations for using the ‘Trials within Cohorts’ design in a clinical trial of an investigational medicinal product
BACKGROUND The 'trials within cohorts' (TwiC) design is a pragmatic approach to randomised trials in which trial participants are randomly selected from an existing cohort. The design has multiple potential benefits, including the option of conducting multiple trials within the same cohort. MAIN TEXT To date, the TwiC design methodology been used in numerous clinical settings but has never be...
متن کاملDeriving Residual Reference Count Garbage Collectors
We present a strategy to derive an efficient reference count garbage collector for any applicative program by only modifying it on the source code level. The key to the approach is to consider the memory as an explicit parameter of the applicative program, thus enabling to implement data structures in terms of memory primitives. On the basis of equivalence preserving source level transformation...
متن کاملTherapeutic importance of peptidomimetics in medicinal chemistry
Today there is a highly elevated demand for synthesis and screening of nature-like biopolymers and their more stable modified derivatives like peptidomimetics because availability of huge amounts of genomic and proteomic data can contribute for research in this area. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein inter...
متن کاملNutritional and medicinal importance of mushrooms
Mushrooms had long been used for medicinal and food purposes since decades. It is now increasingly recognized that correct diet, controls and modulates many functions of human body and consequently participates in the maintenance of state of good health, necessary to reduce the risk of many diseases. Modern pharmacological research confirms large parts of traditional knowledge regarding the med...
متن کاملReview of new regulations for the conduct of clinical trials of investigational medicinal products
The EU Clinical Trials Directive came into force on 1 May 2004 and has changed the face of Clinical Trials of investigational medicinal products in the UK. An enthusiastic registrar or consultant who comes up with an idea for a therapeutic intervention now needs to comply with a complex and demanding set of legal, ethical and regulatory requirements, contravention of which may lead to criminal ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.527